- •
Advances in treatment of autoimmune diseases have led to a reduction in mortality and increased quality of life for these patients, making issues related to long-term preventive health and aging more relevant.
- •
Immune dysregulation from immunosuppressant medications or the underlying diseases may affect clearance of viral infections or innate tumor surveillance among people with autoimmune diseases.
- •
Breast cancer risk does not seem to be increased among women with rheumatoid arthritis or systemic
Reproductive Health Screening in Women with Autoimmune Diseases
Section snippets
Key points
Breast cancer
Breast cancer is the most common malignancy seen in the general female population, with approximately 1.7 million cases diagnosed worldwide in 2012. Known risk factors for the development of breast cancer include family history, age, race, parity, breastfeeding, use of exogenous estrogens, alcohol, sedentary lifestyle, and increased body mass index.1 Given that autoimmune diseases often preferentially affect women and may bear unique relationships with female sex hormones, it is important to
Cervical cancer
Cervical cancer, a virus-associated malignancy, has been studied in autoimmune disease to determine whether the risk is increased owing to immune suppression as well as underlying immune dysfunction. Patients with RA analyzed in a Canadian population did not have an increase in cervical cancer when analyzed retrospectively,12 although later studies of patients with RA in California did show an increased risk of malignancy, including cervical cancer.13 Chang and colleagues14 found no increase in
Adherence and barriers to reproductive health screening
Patients with chronic autoimmune diseases have high health care use rates because of acute management of changing disease activity and monitoring for medication toxicity. In addition, providers and patients alike are becoming increasingly aware of increased risks of cardiovascular disease, stroke, osteoporosis, and infection compared with age-matched healthy individuals. Health care maintenance and screening for other conditions, however prevalent in the general population, may become a lower
Summary
Women with systemic autoimmune diseases face many challenges, and management of active disease and medication toxicity often takes primacy in health care interactions for such conditions. However, because disease-modifying agents have afforded many patients a reduction in disability and improved lifespan, issues of preventive health care and reducing the burden of comorbidities become ever more relevant. Guidelines exist for screening for reproductive malignancies that are common in the
References (43)
- et al.
Cancer risk in systemic lupus: an updated international multi-center cohort study
J Autoimmun
(2013) - et al.
Abnormal cervicovaginal cytology in women with lupus: a retrospective cohort study
Gynecol Oncol
(2001) - et al.
Primary preventive services in patients with systemic lupus erythematosus: Study from a population-based sample in southeast US
Semin Arthritis Rheum
(2013) - et al.
Gene-environment interaction and risk of breast cancer
Br J Cancer
(2016) - et al.
Breast cancer in systemic lupus erythematosus
Oncology
(2013) - et al.
Comparison of breast cancer risk in women with and without systemic lupus erythematosus in a Medicare population
Breast Cancer Res Treat
(2015) - et al.
Standardised incidence ratios (SIRs) for cancer after renal transplantation in systemic lupus erythematosus (SLE) and non-SLE recipients
Lupus Sci Med
(2016) - et al.
Breast cancer in systemic lupus
Lupus
(2017) - et al.
Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis
Arthritis Res Ther
(2015) - et al.
A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis
Arthritis Res Ther
(2008)
Breast cancer risk in rheumatoid arthritis: an update meta-analysis
Biomed Res Int
TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study
Ann Rheum Dis
Association between breast cancer recurrence and immunosuppression in rheumatoid arthritis and inflammatory bowel disease
Arthritis Rheum
Rheumatoid arthritis and the risk of malignancy
Arthritis Rheum
Risk of cancer among rheumatoid arthritis patients in California
Cancer Causes Control
Comparison of cancer incidence among patients with rheumatic disease: a retrospective cohort study
Arthritis Res Ther
Increased incidence of cervical atypia in women with systemic lupus erythematosus treated with chemotherapy
Arthritis Rheum
Systemic lupus erythematosus: predisposition for uterine cervical dysplasia
Lupus
Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection
Arthritis Rheum
Systemic lupus erythematosus and the risk of malignancy
Lupus
Meta-analysis of systemic lupus erythematosus and the risk of cervical neoplasia
Rheumatology (Oxford)
Cited by (4)
Prevalence of cervical HPV infection in women with systemic lupus erythematosus: A systematic review and meta-analysis
2019, Autoimmunity ReviewsCitation Excerpt :Since potential biases or confounders could not be ruled out completely, our results should be verified by further studies. Based on the present results, we encourage rheumatologists and physicians evaluating SLE patients to follow cervical cancer screening guidelines closely, as indicated by research groups like the United States Preventive Services Task Force [42], which recommends that women aged 21 to 65 years should have Pap smear screening every 3 years or, for women aged 30 to 65 years, the Pap smear may be combined with HPV testing, which extends the screening interval to every 5 years. Following these guidelines will allow a preventive health care approach for SLE patients with respect to cervical cancer.
Pregnancy and autoimmune disease, reproductive and hormonal issues
2018, Dubois' Lupus Erythematosus and Related SyndromesFeatures of pericardial lesion in pregnant women
2022, Medical News of North Caucasus